ALLMedicine™ Colon Cancer Center

Sep 18th, 2020 - To identify factors associated with early, intermediate or late recurrence colon cancer recurrence. A total of 1,732 consecutive patients with colon cancer were recruited and followed for a period of 5 years. Recurrence at 1 year (early), from 1 t...

Sep 18th, 2020 - Chemotherapy is one of the most commonly used treatments for patients with advanced colon cancer, yet the toxicity of chemotherapy agents, such as 5‑fluorouracil (5‑FU), limits the effectiveness of chemotherapy. Ginsenoside Rg3 (Rg3) is an active ...

Sep 17th, 2020 - Among the gastrointestinal tract cancers, the risk of colon cancer is strongly dependent on dietary factors. For the first time in the current review, all the original case-control studies, associated with the correlation between total dietary div...

Sep 17th, 2020 - There are few reports comparing safety and efficacy of 2-D and 3-D video technology in laparoscopic right hemicolectomy. The aim of the study was to assess the short-term results of laparoscopic right hemicolectomy (LHR) with intracorporeal anasto...

Sep 17th, 2020 - Obstructive colorectal cancer is locally advanced colorectal cancer with a poor prognosis. The effect of neoadjuvant chemotherapy for obstructive colon cancer is unclear. We conducted the first prospective clinical trial of neoadjuvant chemotherap...

Jul 23rd, 2020 - Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Argilés G,Tabernero J,Labianca R,Hochhauser D,Salazar R,|

May 31st, 2020 - Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduc...

May 29th, 2020 - Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard ch...

May 28th, 2020 - Prospective evaluation of nearly 13,000 individuals with stage III colon cancer found minimal difference in 5-year overall survival (OS) with 3 versus 6 months of adjuvant CAPOX or FOLFOX for the majority of patients, according to the final result...

May 28th, 2020 - Patients with untreated heavily mutated metastatic colorectal cancer (mCRC) lived twice as long without disease progression when they received an immune checkpoint inhibitor instead of chemotherapy, a randomized trial showed.

Sep 18th, 2020 - To identify factors associated with early, intermediate or late recurrence colon cancer recurrence. A total of 1,732 consecutive patients with colon cancer were recruited and followed for a period of 5 years. Recurrence at 1 year (early), from 1 t...

Sep 18th, 2020 - Chemotherapy is one of the most commonly used treatments for patients with advanced colon cancer, yet the toxicity of chemotherapy agents, such as 5‑fluorouracil (5‑FU), limits the effectiveness of chemotherapy. Ginsenoside Rg3 (Rg3) is an active ...

Sep 17th, 2020 - Among the gastrointestinal tract cancers, the risk of colon cancer is strongly dependent on dietary factors. For the first time in the current review, all the original case-control studies, associated with the correlation between total dietary div...

Sep 17th, 2020 - There are few reports comparing safety and efficacy of 2-D and 3-D video technology in laparoscopic right hemicolectomy. The aim of the study was to assess the short-term results of laparoscopic right hemicolectomy (LHR) with intracorporeal anasto...

Sep 17th, 2020 - Obstructive colorectal cancer is locally advanced colorectal cancer with a poor prognosis. The effect of neoadjuvant chemotherapy for obstructive colon cancer is unclear. We conducted the first prospective clinical trial of neoadjuvant chemotherap...

May 31st, 2020 - Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduc...

May 29th, 2020 - Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard ch...

May 28th, 2020 - Prospective evaluation of nearly 13,000 individuals with stage III colon cancer found minimal difference in 5-year overall survival (OS) with 3 versus 6 months of adjuvant CAPOX or FOLFOX for the majority of patients, according to the final result...

May 28th, 2020 - Patients with untreated heavily mutated metastatic colorectal cancer (mCRC) lived twice as long without disease progression when they received an immune checkpoint inhibitor instead of chemotherapy, a randomized trial showed.

Mar 26th, 2020 - Colorectal Cancer Surgery Guidance for colorectal cancer surgery is also split into the three phases of the pandemic. Phase I would include cases needing surgical intervention as soon as feasible, while recognizing that the status of each hospital.